Patents by Inventor Tatyana Naryshkina

Tatyana Naryshkina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cell-based assay for determining activity in the retinoblastoma pathway
    Patent number: 11702666
    Abstract: Disclosed are methods of determining activity of CDK4 and CDK6 variants upon exposure to CDK inhibitors, methods for determining activity of a Rb variant, methods for determining the activity of a p16 variant in a cell, and methods for determining the sensitivity of a CDK4 variant or a CDK6 variant to p16 in a cell. Stable cell lines for determining activity of CDK4 variants, CDK6 variants, Rb variants, and p16 variants are also disclosed.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: July 18, 2023
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventor: Tatyana Naryshkina
  • Cell-based assay for determining activity in the retinoblastoma pathway
    Patent number: 11692195
    Abstract: Disclosed are methods of determining activity of CDK4 and CDK6 variants upon exposure to CDK inhibitors, methods for determining activity of a Rb variant, methods for determining the activity of a p16 variant in a cell, and methods for determining the sensitivity of a CDK4 variant or a CDK6 variant to p16 in a cell. Stable cell lines for determining activity of CDK4 variants, CDK6 variants, Rb variants, and p16 variants are also disclosed.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: July 4, 2023
    Assignee: Medical Diagnostics Laboratories, LLC
    Inventor: Tatyana Naryshkina
  • Novel Cell-Based Assay for Determining Activity in the Retinoblastoma Pathway
    Publication number: 20220073935
    Abstract: Disclosed are methods of determining activity of CDK4 and CDK6 variants upon exposure to CDK inhibitors, methods for determining activity of a Rb variant, methods for determining the activity of a p16 variant in a cell, and methods for determining the sensitivity of a CDK4 variant or a CDK6 variant to p16 in a cell. Stable cell lines for determining activity of CDK4 variants, CDK6 variants, Rb variants, and p16 variants are also disclosed.
    Type: Application
    Filed: October 15, 2021
    Publication date: March 10, 2022
    Applicant: Medical Diagnostic Laboratories, LLC
    Inventor: Tatyana Naryshkina
  • Novel Cell-Based Assay for Determining Activity in the Retinoblastoma Pathway
    Publication number: 20220049261
    Abstract: Disclosed are methods of determining activity of CDK4 and CDK6 variants upon exposure to CDK inhibitors, methods for determining activity of a Rb variant, methods for determining the activity of a p16 variant in a cell, and methods for determining the sensitivity of a CDK4 variant or a CDK6 variant to p16 in a cell. Stable cell lines for determining activity of CDK4 variants, CDK6 variants, Rb variants, and p16 variants are also disclosed.
    Type: Application
    Filed: October 13, 2021
    Publication date: February 17, 2022
    Applicant: Medical Diagnostic Laboratories, LLC
    Inventor: Tatyana Naryshkina
  • Cell-based assay for determining activity in the retinoblastoma pathway
    Patent number: 11180766
    Abstract: Disclosed are methods of determining activity of CDK4 and CDK6 variants upon exposure to CDK inhibitors, methods for determining activity of a Rb variant, methods for determining the activity of a p16 variant in a cell, and methods for determining the sensitivity of a CDK4 variant or a CDK6 variant to p16 in a cell. Stable cell lines for determining activity of CDK4 variants, CDK6 variants, Rb variants, and p16 variants are also disclosed.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: November 23, 2021
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventor: Tatyana Naryshkina
  • NOVEL CELL-BASED ASSAY FOR DETERMINING ACTIVITY IN THE RETINOBLASTOMA PATHWAY
    Publication number: 20190144876
    Abstract: Disclosed are methods of determining activity of CDK4 and CDK6 variants upon exposure to CDK inhibitors, methods for determining activity of a Rb variant, methods for determining the activity of a p16 variant in a cell, and methods for determining the sensitivity of a CDK4 variant or a CDK6 variant to p16 in a cell. Stable cell lines for determining activity of CDK4 variants, CDK6 variants, Rb variants, and p16 variants are also disclosed.
    Type: Application
    Filed: November 16, 2018
    Publication date: May 16, 2019
    Applicant: Medical Diagnostic Laboratories, LLC
    Inventor: Tatyana Naryshkina
  • Novel thermophilic proteins and the nucleic acids encoding them
    Publication number: 20070202508
    Abstract: The disclosed invention relates to the fields of molecular biology and biochemistry. Thermophilic proteins and the nucleic acids encoding them are disclosed. The thermophilic proteins are from, or derived from, a bacteriophage, YS40, that infects the thermophilic bacterium Thermus thermophilus. These proteins have enhances stability, particularly at high temperatures.
    Type: Application
    Filed: February 24, 2006
    Publication date: August 30, 2007
    Inventors: Arcady Mushegian, Jing Liu, Tatyana Naryshkina, Konstantin V. Saverinov